Last reviewed · How we verify

Cyclosporine - cyclosporine microemulsion

Novartis · FDA-approved active Small molecule

Cyclosporine - cyclosporine microemulsion is a Calcineurin inhibitor Small molecule drug developed by Novartis. It is currently FDA-approved for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Rheumatoid arthritis, Psoriasis.

Cyclosporine inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription.

Cyclosporine inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Rheumatoid arthritis, Psoriasis.

At a glance

Generic nameCyclosporine - cyclosporine microemulsion
SponsorNovartis
Drug classCalcineurin inhibitor
TargetCalcineurin (protein phosphatase 2B)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Cyclosporine binds to cyclophilin and forms a complex that inhibits calcineurin, a phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). This prevents NFAT translocation to the nucleus and subsequent IL-2 and other cytokine gene transcription, thereby suppressing T-cell mediated immune responses. The microemulsion formulation improves oral bioavailability and reduces food-dependent variability compared to conventional formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cyclosporine - cyclosporine microemulsion

What is Cyclosporine - cyclosporine microemulsion?

Cyclosporine - cyclosporine microemulsion is a Calcineurin inhibitor drug developed by Novartis, indicated for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Rheumatoid arthritis, Psoriasis.

How does Cyclosporine - cyclosporine microemulsion work?

Cyclosporine inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription.

What is Cyclosporine - cyclosporine microemulsion used for?

Cyclosporine - cyclosporine microemulsion is indicated for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Rheumatoid arthritis, Psoriasis, Atopic dermatitis, Nephrotic syndrome (minimal change disease).

Who makes Cyclosporine - cyclosporine microemulsion?

Cyclosporine - cyclosporine microemulsion is developed and marketed by Novartis (see full Novartis pipeline at /company/novartis).

What drug class is Cyclosporine - cyclosporine microemulsion in?

Cyclosporine - cyclosporine microemulsion belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Cyclosporine - cyclosporine microemulsion in?

Cyclosporine - cyclosporine microemulsion is FDA-approved (marketed).

What are the side effects of Cyclosporine - cyclosporine microemulsion?

Common side effects of Cyclosporine - cyclosporine microemulsion include Nephrotoxicity/renal dysfunction, Hypertension, Tremor, Headache, Gingival hyperplasia, Hirsutism.

What does Cyclosporine - cyclosporine microemulsion target?

Cyclosporine - cyclosporine microemulsion targets Calcineurin (protein phosphatase 2B) and is a Calcineurin inhibitor.

Related